Johnson & Johnson Target of Unusually Large Options Trading (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJGet Rating) was the recipient of some unusual options trading activity on Tuesday. Investors acquired 62,583 call options on the company. This is an increase of 86% compared to the typical daily volume of 33,585 call options.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $168.31 on Wednesday. The firm has a market capitalization of $440.04 billion, a P/E ratio of 23.44, a P/E/G ratio of 3.21 and a beta of 0.56. The company has a 50-day simple moving average of $175.98 and a 200-day simple moving average of $171.06. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping the consensus estimate of $2.23 by $0.12. The business had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The company’s quarterly revenue was down 4.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.13 earnings per share. As a group, equities analysts expect that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be issued a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s payout ratio is 62.95%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of Johnson & Johnson stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the transaction, the vice president now directly owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, EVP Kathryn E. Wengel sold 16,410 shares of the business’s stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,366,753.62. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction on Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the transaction, the vice president now directly owns 40,133 shares in the company, valued at $6,869,966.94. The disclosure for this sale can be found here. Insiders have sold a total of 233,611 shares of company stock valued at $40,960,735 over the last ninety days. Corporate insiders own 0.35% of the company’s stock.

Institutional Investors Weigh In On Johnson & Johnson

Institutional investors and hedge funds have recently bought and sold shares of the business. RKL Wealth Management LLC lifted its holdings in Johnson & Johnson by 2.1% in the 2nd quarter. RKL Wealth Management LLC now owns 48,233 shares of the company’s stock valued at $8,562,000 after acquiring an additional 1,010 shares during the last quarter. Geller Advisors LLC raised its holdings in Johnson & Johnson by 7.5% during the 2nd quarter. Geller Advisors LLC now owns 9,260 shares of the company’s stock worth $1,644,000 after buying an additional 648 shares during the period. Simon Quick Advisors LLC raised its holdings in Johnson & Johnson by 296.9% during the 2nd quarter. Simon Quick Advisors LLC now owns 8,739 shares of the company’s stock worth $1,495,000 after buying an additional 6,537 shares during the period. Lokken Investment Group LLC raised its holdings in Johnson & Johnson by 1.6% during the 2nd quarter. Lokken Investment Group LLC now owns 12,968 shares of the company’s stock worth $2,302,000 after buying an additional 201 shares during the period. Finally, Keebeck Alpha LP raised its holdings in Johnson & Johnson by 13.4% during the 2nd quarter. Keebeck Alpha LP now owns 4,442 shares of the company’s stock worth $788,000 after buying an additional 525 shares during the period. 67.94% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Atlantic Securities reduced their target price on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 19th. Bank of America dropped their price target on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research note on Friday, October 14th. Morgan Stanley dropped their price target on shares of Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 6th. Raymond James dropped their price target on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research note on Wednesday, October 19th. Finally, Citigroup lifted their price target on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research note on Monday, December 12th. Seven analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $181.75.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.